Transforming ADHD Care: Viloxazine ER vs Atomoxetine Roundtable Discussion

In this roundtable discussion focused on the "Extended-Release (ER) Viloxazine Compared With Atomoxetine for Attention-Deficit/Hyperactivity Disorder (ADHD)" study published in July 2023 in volume 37 of CNS Drugs, experts Dr Gregory Mattingly, Dr Richard Price, and Dr Birgit Amann examine the evolving ADHD treatment landscape. They compare viloxazine ER with atomoxetine, offering insights into a range of current treatments, which include both psychostimulants and nonstimulants. The panel emphasizes the critical importance of patient-specific factors and the implications of increasing ADHD diagnoses on treatment decisions. A key part of the discussion is devoted to the study's findings, particularly the efficacy, response time, and safety of viloxazine ER and atomoxetine, and viloxazine ER’s effectiveness in managing symptoms of ADHD in adults and children, specifically those with combined-type ADHD. Furthermore, the experts explore the future of ADHD treatment, addressing the field's unmet needs and providing vital insights into potential advancements and the challenges encountered in clinical practice from the perspectives of both clinicians and patients. To read the full article, please visit https://link.springer.com/article/10.1007/s40263-023-01023-6.

ADHD Unmasked: Current ADHD Treatment Landscape

In this roundtable discussion featuring a panel of experts, Dr Gregory Mattingly, Dr Richard Price, and Dr Birgit Amann delve into the evolving landscape of ADHD treatment. The panelists discuss current treatment options, including psychostimulants and nonstimulants such as viloxazine ER, and share insights on their clinical decision-making processes. Key topics include patient-specific factors influencing treatment choices, the impact of increasing ADHD diagnoses on clinical decision-making, and recent significant advancements expected to influence ADHD management practices.

Real-World Data Deep Dive: Viloxazine ER Compared With Atomoxetine for ADHD Study 

In this roundtable discussion featuring a panel of experts, Dr Gregory Mattingly, Dr Richard Price, and Dr Birgit Amann explore key findings from the real-world study comparing viloxazine ER with atomoxetine for ADHD treatment in adult and pediatric patients. The panelists discuss the study results including efficacy of viloxazine ER in managing inattention and hyperactivity/impulsivity, its response time compared to atomoxetine, and its tolerability and safety profile. This session spotlights the implications of the study findings on clinical decision-making and the potential impact on future ADHD treatment approaches, particularly for patients with combined-type ADHD.

Navigating ADHD Care Forward: The Future of ADHD

In this roundtable discussion featuring a panel of experts, Dr Gregory Mattingly, Dr Richard Price, and Dr Birgit Amann focus on the evolving future of the ADHD landscape and address current unmet needs in ADHD treatment for both adult and pediatric patients. The panelists discuss the challenges faced in clinical practice, highlighting clinician and patient perspectives. This session emphasizes the current unmet needs in the overall ADHD landscape, prioritizing both clinicians' and patients' perspectives, and highlights concluding key takeaways.